ClinicalTrials.gg
RecruitingNCT06441552RESTROUpdated Oct 3, 2025

The Natural History of Recovery After Stroke

An observational study in Cerebral Vascular Accident (CVA)/Stroke, sponsored by Adi Negev-Nahalat Eran. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Adi Negev-Nahalat Eran · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Stroke with a site in Israel — 12 open to participants now, 21 under way, 3 of them phase 3. Stroke · Israel.

Planned enrollment
16th of 36
200 · median 196
Started
2024
with 3 others
Observational
38 of 127
3 open now
Primary completion
2027-01
later than 10 of 20 live
Registered
116th of 127
by date
Lead sponsor
3 of 127
Adi Negev-Nahalat Eran

Among the 127 studies in Stroke with a site in Israel, this one is the 16th largest by planned enrollment of the 36 observational ones that give a count, is one of 4 that started in 2024, is one of 38 observational ones, reaches primary completion later than 10 of the 20 other live ones, and was the 116th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

12 of the 127 studies in Stroke with a site in Israel are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Stroke with a site in Israel, or all of them as a file.
02

Study summary

The goal of this longitudinal observational study is to learn the course of recovery after stroke. Specifically, in this study we will learn and describe the changes in cognitive, motor and sensory function over time in stroke patients.

Read the detailed description

This study constitutes the first step in the RESTRO project: Evaluation of an accessible and affordable neurorehabilitation program to promote recovery and to enhance the quality of life after stroke. In this study, we will monitor sensorimotor and cognitive functions of Stroke patients along the first 6 to 12 month following their stroke. Data from three primary sites will be collected and compared in several time points, and its relation to the type and intensity of the rehabilitation program, usually provided in each site, will be tested.

03

Conditions studied

  • Cerebral Vascular Accident (CVA)/Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Stroke survivors and healthy adults.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18 years of age
  • Independent in all activities of daily living before the stroke.
  • In- and out-patients at Adi-Negev Nahalat-Eran rehabilitation center, with first ever stroke, or with a recurrent stroke that did not lead to disability (were independent in ADL before the second stroke).
  • Medically stable
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • The presence of any degenerative neurological condition, neuropathy, myopathy or Polio that are not secondary to stroke, excluding diabetic related changes.
  • Traumatic brain injury and/or extra-cerebral hemorrhage.
  • Significant psychiatric condition, including alcoholism and drug abuse.
  • Any severe orthopedic condition (such as amputation or severe pain that limits activity) or chronic pain syndrome.
  • Participation in another interventional study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Ofakim

    Non-interventional group, recruited at Adi-Negev Rehabilitation Center, Israel.

    Other: non-interventional

  • Haifa

    Non-interventional group, recruited at Rambam Health Care Campus, Israel.

    Other: non-interventional

  • Hebron

    Non-interventional group, recruited through Green Land Society for Health Development, Palestine.

    Other: non-interventional

Interventions

  • Othernon-interventional

    non-interventional

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment (FMA)

    Fugl-Meyer Assessment: Motor score is on a 0-100 scale. High score is better.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  2. Action Research Arm Test (ARAT)

    Action Research Arm Test Score is on a 0-57 scale. High score is better.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  3. 10-meter walk test (10MWT)

    Outcome is the average walking velocity over 10 meters. Measured in m/sec.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

Secondary outcomes

  1. National Institutes of Health Stroke Scale (NIHSS)

    measure of stroke severity on a 0-42 scale, with lower scores indicates lower severity (lower is better).

    Time frame: Baseline (<3weeks)

  2. The Stroke Self-Efficacy Questionnaire (SSEQ)

    This is a self-reported ability perception scale. Outcome range is 0-130 with higher scores indicate a better self-perceived ability.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  3. The Nine Hole Peg Test (NHPT)

    This is an upper extremity dexterity test. Outcome is the time taken to complete the task. Measured in sec.

    Time frame: Baseline (<3weeks), 1-year

  4. The Functional Dexterity Test (FDT)

    This is an upper extremity dexterity test. Outcome is the time taken to complete the task. Measured in sec.

    Time frame: Baseline (<3weeks), 1-year

  5. The Behavioral Inattention Test (BIT)

    This is an instrument aimed at detecting visual neglect. In this study we use only two subsections of the test: star cancellation (scored on a 0-54 scale) and representational drawing (scored on a 0-3 scale). For both, higher scores are better.

    Time frame: Baseline (<3weeks)

  6. The Ashworth scale

    This instrument is used to detect spasticity (increased muscle tone). Outcome is 0-4 scale, with lower scores means better outcome (less spasticity).

    Time frame: Baseline (<3weeks)

  7. Kinetics-fingers1

    To measure fingers kinetics, we will use a custom-built device that measures finger force for flexion and extension. Outcome is the force in Newtons (N) generated by each finger.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  8. Kinetics-fingers2

    To measure fingers kinetics, we will use a custom-built device that measures finger force for flexion and extension. Outcome measure is the Individuation Index, measured in arbitrary units (a.u.). The individuation index is calculated as the ratio between the forces generated by the non-instructed digits and the force generated by the instructed digit. This index evaluates the ability to generate force in each digit independently of the other digits.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  9. Kinetics-grip

    Grip force will be measured using the microFET Digital HandGrip Dynamometer (Hoggan Scientific). Outcome is the maximal force in Newtons.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  10. Kinematics-reaching

    Kinematic measurements of upper extremity reaching task: Kinematic measures will be extracted using markerless pose estimation algorithms (such as OpenPose and MediaPipe). Reaching error (distance of the hand from the target) and reaching extent (maximum distance of the wriest from the shoulder). Measured in mm.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  11. Kinematics-duration

    Kinematic measurements of upper extremity reaching tasks: Kinematic measures will be extracted using markerless pose estimation algorithms (such as OpenPose and MediaPipe). Reaching duration. Measured in seconds.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  12. Kinematics-smoothness

    Kinematic measurements of upper extremity reaching tasks: Kinematic measures will be extracted using markerless pose estimation algorithms (such as OpenPose and MediaPipe). Reaching smoothness as the integrated jerk (as described by Platz et al. 1994, Dimensions are L\^2/T\^6) and the spectral arch length (as described by Balasubramanian et al. 2015).

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  13. Kinematics-Inter-joint coordination

    Kinematic measurements of upper extremity reaching tasks: Kinematic measures will be extracted using markerless pose estimation algorithms (such as OpenPose and MediaPipe). Inter-joint coordination will be measured through computing the cross correlation between elbow, writs and shoulder joint angles and the proportion of time when joints flexed or extend together. Arbitrary units.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  14. Rehabilitation-intensity

    Number of rehabilitative sessions per week, in total and for each modality separately (e.g., physical therapy, occupational therapy, etc.)

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  15. Rehabilitation-time

    Time, in minutes, of each therapy session.

    Time frame: one or more of: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  16. Rehabilitation-period

    Period of time (in month) for which the participant received therapy.

    Time frame: one or more of: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  17. Supporting data-age

    Age at admission, in years.

    Time frame: Baseline

  18. Supporting data-sex

    Biological Male or Female

    Time frame: Baseline

  19. Supporting data-time1

    time from stroke onset in days

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  20. Supporting data-time2

    other time periods (e.g., inpatient time, rehabilitation duration, etc.) in Months.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  21. anthropometric data-height

    Height in cm

    Time frame: Baseline

  22. anthropometric data-weight

    Weight in kg

    Time frame: Baseline

  23. supporting data-directional

    affected brain side: L/R/Both affected body side: L/R/Both hand dominance: L/R leg dominance: L/R

    Time frame: Baseline

  24. supporting data-medical history

    Any relevant history of illnesses.

    Time frame: Baseline

  25. Cognition-impairment

    Montreal Cognitive Assessment (MoCA). 0-30 scale with higher values indicate better cognitive state.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  26. Cognition-inhibition1

    Percent correct responses in an anti-saccade computerized task.

    Time frame: one or more of : Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  27. Cognition-inhibition2

    Reaction time (in msec) in an anti-saccade computerized task.

    Time frame: one or more of : Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  28. Timed up and Go test (TUG)

    Time taken to complete the TUG task. Measured in seconds.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  29. Gait Specific attentional profile (G-SAP)

    This is a questioner aimed at evaluating the attentional profile of the patient during walking. It has several subscales measured on a Likert 5-point scale. Total score range is 11-55 with lower values indicate better outcome.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  30. Gait analysis-temporal

    Gait analysis while participants are walking on a treadmill (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany) with an embedded force sensors array. Temporal measures include step and stride time. Measured in seconds.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  31. Gait analysis-spatial

    Gait analysis while participants are walking on a treadmill (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany) with an embedded force sensors array. Spatial measures include step and stride length and width. Measured in meters.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  32. Gait analysis-steadiness

    Gait analysis while participants are walking on a treadmill (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany) with an embedded force sensors array. Steadiness is measured by calculating the maximal Lyapunov exponent of the center of pressure dynamics (as described by Rosenstein et al. 1993). Units of measure are arbitrary.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  33. Gaze-angle1

    Gaze behavior during walking using a mobile eye-tracker (Pupil Invisible, Pupil Labs, Germany). Head, eye and gaze (head and eye combined) angles on the sagittal and horizontal planes will be measured. Outcome in degrees.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  34. Gaze-angle2

    Gaze behavior during walking using a mobile eye-tracker (Pupil Invisible, Pupil Labs, Germany). Gaze angles will be measured relative to the vanishing point. Outcome in %.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  35. Gaze-downward

    Gaze behavior during walking using a mobile eye-tracker (Pupil Invisible, Pupil Labs, Germany). Time spent looking onto the walking surface. Outcome in %.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  36. Gaze-look-ahead distance

    Gaze behavior during walking using a mobile eye-tracker (Pupil Invisible, Pupil Labs, Germany). Look-ahead distance. Outcome in meters.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  37. Balance-Berg

    Berg Balance Scale (BBS) measured on a 0-56 scale with higher score represent better outcome.

    Time frame: baseline

  38. Balance-postural steadiness1

    Postural Sway (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany). Outcome is sway range in mm.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  39. Balance-postural steadiness2

    Postural Sway (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany). Outcome is sway velocity in mm/sec.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  40. Balance-postural steadiness3

    Postural Sway (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany). Outcome is sway area in mm\^2.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  41. Balance-postural steadiness4

    Postural Sway (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany). Outcome is the short-term diffusion coefficients, as described by Collins and De-Luka (1993), measured in mm\^2/sec.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  42. Habitual activity1

    Monitoring habitual activity during hospital stay. Time spent walking, sitting and laying in hours/day. Measured over 3-5 consecutive days.

    Time frame: one or more of :Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  43. Habitual activity2

    Monitoring habitual activity during hospital stay. Distance walked in meters/day. Measured over 3-5 consecutive days.

    Time frame: one or more of :Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  44. Sensory-tactile

    Sensory acuity will be measured using Semmes-Weinstein monofilament. Outcome is in grams.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  45. Coordination-LE1

    LEMOCOT- Lower Extremity Motor Coordinating Test. Outcome is the number of touches (count).

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  46. Coordination-LE2

    LEMOCOT- Lower Extremity Motor Coordinating Test. Outcome is the touches' errors (distance from the middle of the target), measured in mm. To measure errors, the LEMOCOT will be performed on an array of force sensors (Zebris FDM-T Treadmill, Zebris Medical GmbH, Germany) that detects the touches position.

    Time frame: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  47. Reticulospinal excitability

    Response enhancement following a startling auditory stimuli (StartReact measure). Reaction time is measured in msec based on EMG signal from the wrist extensors and biceps (gtech USB-Amp). The StartReact measure is the enhancement in reaction time in the startle condition (LED+105Db auditory stimulus) compared to a control condition (LED+80Db auditory stimulus)

    Time frame: one or more of: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  48. Muscle controllability1

    The ability to control a cursor in a virtual environment using EMG recordings from wrist extensors and biceps (Trigno Wireless EMG System, Delsys, USA). Outcome is success rate in %.

    Time frame: one or more of: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  49. Muscle controllability2

    The ability to control a cursor in a virtual environment using EMG recordings from wrist extensors and biceps (Trigno Wireless EMG System, Delsys, USA). Outcome is time to target sec.

    Time frame: one or more of: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  50. Muscle controllability3

    The ability to control a cursor in a virtual environment using EMG recordings from wrist extensors and biceps (Trigno Wireless EMG System, Delsys, USA). Outcome is path length in cm.

    Time frame: one or more of: Baseline (<3weeks), 1-month, 3-month, 6-month, 1-year

  51. Neuroimaging

    CT/MRI based structural neuroimaging. Outcomes are the areas affected by stroke.

    Time frame: one or more of :1-month, 3-month, 6-month, 1-year

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Rosenstein, M. T., Collins, J. J., & De Luca, C. J. (1993). A practical method for calculating largest Lyapunov exponents from small data sets. Physica D: Nonlinear Phenomena, 65(1-2), 117-134.
  • Platz T, Denzler P, Kaden B, Mauritz KH. Motor learning after recovery from hemiparesis. Neuropsychologia. 1994 Oct;32(10):1209-23. doi: 10.1016/0028-3932(94)90103-1. PubMed 7845561 ↗
  • Balasubramanian S, Melendez-Calderon A, Roby-Brami A, Burdet E. On the analysis of movement smoothness. J Neuroeng Rehabil. 2015 Dec 9;12:112. doi: 10.1186/s12984-015-0090-9. PubMed 26651329 ↗
  • Collins JJ, De Luca CJ. Open-loop and closed-loop control of posture: a random-walk analysis of center-of-pressure trajectories. Exp Brain Res. 1993;95(2):308-18. doi: 10.1007/BF00229788. PubMed 8224055 ↗

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.

Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 35 months is below that.

Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
Jun 4, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06441552
Lead sponsor
Adi Negev-Nahalat Eran
Collaborators
Ben-Gurion University of the Negev, Technion, Israel Institute of Technology
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Feb 1, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 3, 2025

Study contacts

Simona Bar-Haim, PhD
Contact
barhaims@bgu.ac.il
972-54-470-2553
Lior Smuelof, PhD
Contact
shmuelof@gmail.com
Simona Bar-Haim, PhD
principal investigator · Ben-Gurion University of the Negev
Lior Smuelof, PhD
principal investigator · Ben-Gurion University of the Negev
Shirley Handelzalts, PhD
principal investigator · Ben-Gurion University of the Negev
Firas Mawase, PhD
principal investigator · Technion, Israel Institute of Technology
Akram Amro, PhD
principal investigator · Green Land Society for Health Development

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion